Adrenoleukodystrophy. The chain shortening of erucic acid (22:1(n−9)) and adrenic acid (22:4(n−6)) is deficient in neonatal adrenoleukodystrophy and normal in X-linked adrenoleukodistrophy skin fibroblasts-Reference-Cited by-同舟云学术

Adrenoleukodystrophy. The chain shortening of erucic acid (22:1(n−9)) and adrenic acid (22:4(n−6)) is deficient in neonatal adrenoleukodystrophy and normal in X-linked adrenoleukodistrophy skin fibroblasts

Published:1989-03 Issue:1 Volume:1002 Page:79-83
ISSN:0005-2760
Container-title:Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism
language:en
Short-container-title:Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism

Author:

Christensen Erik,Grønn Morten,Hagve Tor-Arne,Kase Bengt Frode,Christophersen Bjørn O.

Publisher

Elsevier BV

Subject

Endocrinology,Biochemistry,Biophysics

Reference28 articles.

1. Lignoceroyl-CoASH ligase: enzyme defect in fatty acid β-oxidation system in X-linked childhood adrenoleukodystrophy

2. X-Linked adrenoleukodystrophy: Defective peroxisomal oxidation of very long chain fatty acids but not of very long chain fatty acyl-CoA esters

3. Peroxisomal β-oxidation enzyme proteins in the Zellweger syndrome

4. Deficient activities and proteins of peroxisomal β-oxidation enzymes in infants with Zellweger syndrome

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Species of Phospholipids with Very Long Chain Fatty Acids in Skin Fibroblasts of Zellweger Syndrome;Lipids;2013-10-13

2. Modifying the Peroxisomes by Cell & Tissue Culture;Advances in Experimental Medicine and Biology;2003

3. Studies on the transport of acetyl groups from peroxisomes to mitochondria in isolated liver cells oxidizing the polyunsaturated fatty acid 22:4n–6;Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids;2001-10

4. Chain separation of monounsaturated fatty acid methyl esters by argentation thin-layer chromatography;Journal of Chromatography A;2001-01

5. Therapeutic developments in peroxisome biogenesis disorders;Expert Opinion on Investigational Drugs;2000-09